Abstract
Translational pharmacological research on traditional medicines lays the foundation for precisely understanding how the medicines function in the body to deliver therapeutic benefits. Borneolum syntheticum (Bingpian) is commonly used in Chinese herbal medicines for coronary heart disease, but its specific cardiovascular impact remains poorly understood. Isoborneol, a constituent of Bingpian, has been found to reduce lipid accumulation in macrophages in vitro, but its oral bioavailability is limited. This investigation aimed to evaluate anti-atherosclerotic effects of Bingpian, based on understanding its first-pass metabolism. Human subjects orally received an herbal medicine containing Bingpian and their plasma samples were analyzed to identify the major circulating compounds of Bingpian, with the metabolism that was also characterized in vitro and in mice. The identified compounds were evaluated for their ability to inhibit macrophage foam-cell formation induced by oxidized low-density lipoprotein. Furthermore, the anti-atherosclerotic effect of repeatedly dosed Bingpian was assessed in ApoE−/− mice fed a high-fat diet. In human subjects, the major circulating compounds of Bingpian were metabolites, rather than their precursor constituents borneol and isoborneol. These constituents were efficiently absorbed in the intestinal tract but underwent significant first-pass metabolism, involving UGT2B7-mediated glucuronidation into borneol-2-O-glucuronide and isoborneol-2-O-glucuronide, respectively, and CYP2A6/2B6/3A-mediated oxidation both into camphor. Despite their poor membrane permeability, hepatic efflux of borneol-2-O-glucuronide and isoborneol-2-O-glucuronide into the systemic circulation was enhanced by MRP3/4. The circulating metabolites, particularly their combinations, markedly inhibited macrophage foam-cell formation induced by oxidized low-density lipoprotein in vitro. Sub-chronic administration of Bingpian (30 mg·kg−1·d−1, i.g.) for 12 weeks significantly decreased atherosclerotic lesion size and enhanced plaque stability in ApoE−/− mice. Systemic exposure to Bingpian metabolites in mice closely resembles that in humans, suggesting that the pharmacodynamic effects of Bingpian in mice are likely applicable to humans. Overall, the cardiovascular benefits of Bingpian involve reducing atherosclerosis by inhibiting foam-cell formation through its metabolites. This investigation supports that oral Bingpian could be a druggable agent for reducing atherosclerosis.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Atanasov AG, Zotchev SB, Dirsch VM, International Natural Product Sciences Taskforce, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20:200–16.
Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J Nat Prod. 2020;83:770–803.
Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China (Edition 2020). Volume I. Beijing: China Medical Science Press; 2020.
Mei YQ, Li L, Fan LH, Fan WX, Liu LC, Zhang FL, et al. The history, stereochemistry, ethnopharmacology and quality assessment of borneol. J Ethnopharmacol. 2023;300:115697.
Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China (Edition 2020). Volume I. Beijing: China Medical Science Press; 2020. p152.
Liu SY, Long Y, Yu S, Zhang DK, Yang QY, Ci ZM, et al. Borneol in cardio-cerebrovascular diseases: pharmacological actions, mechanisms, and therapeutics. Pharmacol Res. 2021;169:105627.
Wang YF, Li ZR, Liu BX, Wu RM, Gong HF, Su ZH, et al. Isoborneol attenuates low-density lipoprotein accumulation and foam cell formation in macrophages. Drug Des Devel Ther. 2020;14:167–73.
Cheng C, Liu XW, Du FF, Li MJ, Xu F, Wang FQ, et al. Sensitive assay for measurement of volatile borneol, isoborneol, and the metabolite camphor in rat pharmacokinetic study of Borneolum (Bingpian) and Borneolum syntheticum (synthetic Bingpian). Acta Pharmacol Sin. 2013;34:1337–48.
Hou MZ, Chen LL, Chang C, Zan JF, Du SM. Pharmacokinetic and tissue distribution study of eight volatile constituents in rats orally administrated with the essential oil of Artemisiae argyi Folium by GC-MS/MS. J Chromatogr B. 2021;1181:122904.
Ren J, Hu CL, Zhang ZP, Chen R, Yang SB, Miao ZY, et al. Development and validation an LC-MS/MS method to quantify (+)-borneol in rat plasma: application to a pharmacokinetic study. J Chromatogr B. 2019;1109:121–7.
Zhong CC, Chen F, Yang JL, Jia WW, Cheng C, Du FF, et al. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species. Acta Pharmacol Sin. 2018;39:1048–63.
Zhang NT, Cheng C, Olaleye OE, Sun Y, Li L, Huang YH, et al. Pharmacokinetics-based identification of potential therapeutic phthalides from XueBiJing, a Chinese herbal injection used in sepsis management. Drug Metab Dispos. 2018;46:823–34.
Diao XX, Deng P, Xie C, Li XL, Zhong DF, Zhang YF, et al. Metabolism and pharmacokinetics of 3-n-butylphthalide (NBP) in humans: the role of cytochrome P450s and alcohol dehydrogenase in biotransformation. Drug Metab Dispos. 2013;41:430–44.
Lan XF, Olajide OE, Du FF, Yang JL, Shi YH, Yang W, et al. Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing LianhuaQingwen capsule. Acta Pharmacol Sin. 2021;42:2155–72.
Dong JJ, Olaleye OE, Jiang RR, Li J, Lu C, Du FF, et al. Glycyrrhizin has a high likelihood to be a victim of drug-drug interactions mediated by hepatic OATP1B1/1B3. Br J Pharmacol. 2018;175:3486–503.
Jia WW, Du FF, Liu XW, Jiang RR, Xu F, Yang JL, et al. Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. Drug Metab Dispos. 2015;43:669–78.
Guo B, Li C, Wang GJ, Chen LS. Rapid and direct measurement of free concentrations of highly protein-bound fluoxetine and its metabolite norfluoxetine in plasma. Rapid Commun Mass Spectrom. 2006;20:39–47.
Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659–61.
Ma SG, Chowdhury SK. Analytical strategies for assessment of human metabolites in preclinical safety testing. Anal Chem. 2011;83:5028–36.
Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China (Edition 2020). ume IV. Beijing: China Medical Science Press; 2020. p. p466–72.
Gao C, Huang QX, Liu CH, Kwong CHT, Yue LD, Wan JB, et al. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. Nat Commun. 2020;11:2622.
Matarazzo S, Quitadamo MC, Mango R, Ciccone S, Novelli G, Biocca S. Cholesterol-lowering drugs inhibit lectin-like oxidized low-density lipoprotein-1 receptor function by membrane raft disruption. Mol Pharmacol. 2012;82:246–54.
Zheng SZ, Du YF, Ye Q, Zha K, Feng J. Atorvastatin enhances foam cell lipophagy and promotes cholesterol efflux through the amp-activated protein kinase/mammalian target of rapamycin pathway. J Cardiovasc Pharmacol. 2021;77:508–18.
Jeong SJ, Kim S, Park JG, Jung IH, Lee MN, Jeon S, et al. Prdx1 (peroxiredoxin 1) deficiency reduces cholesterol efflux via impaired macrophage lipophagic flux. Autophagy. 2018;14:120–33.
Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol. 2004;24:1006–14.
Zheng G, Zhao Y, Li Z, Hua Y, Zhang J, Miao Y, et al. GLSP and GLSP-derived triterpenes attenuate atherosclerosis and aortic calcification by stimulating ABCA1/G1-mediated macrophage cholesterol efflux and inactivating RUNX2-mediated VSMC osteogenesis. Theranostics. 2023;13:1325–41.
Wang D, Yang Y, Lei Y, Tzvetkov NT, Liu X, Yeung AWK, et al. Targeting foam cell formation in atherosclerosis: therapeutic potential of natural products. Pharmacol Rev. 2019;71:596–670.
Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Prim. 2019;5:56.
Cheng C, Ren C, Li M-Z, Liu Y-H, Yao R-Q, Yu Y, et al. Pharmacologically significant constituents collectively responsible for anti-sepsis action of XueBiJing, a Chinese herb-based intravenous formulation. Acta Pharmacol Sin 2024;45:1077–92.
Li C, Jia WW, Yang JL, Cheng C, Olaleye OE. Multi-compound and drug-combination pharmacokinetic research on Chinese herbal medicines. Acta Pharmacol Sin. 2022;43:3080–95.
Li C, Yang JL, Cheng C, Jia WW. Pharmacokinetic research on investigational Chinese herbal medicines. Chin J Drug Eval. 2023;40:457–69.
Meech R, Hu DG, McKinnon RA, Mubarokah SN, Haines AZ, Nair PC, et al. The UDP-Glycosyltransferase (UGT) Superfamily: new members, new functions, and novel paradigms. Physiol Rev. 2019;99:1153–222.
Hu DG, Hulin JU-A, Nair PC, Haines AZ, McKinnon RA, Mackenzie PI, et al. The UGTome: The expanding diversity of UDP glycosyltransferases and its impact on small molecule metabolism. Pharmacol Ther. 2019;204:107414.
Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther. 1989;251:477–83.
van Heek M, Farley C, Compton DS, Hoos L, Alton KB, Sybertz EJ, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol. 2000;129:1748–54.
Hirayama F, Koshio H, Ishihara T, Hachiya S, Sugasawa K, Koga Y, et al. Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. J Med Chem. 2011;54:8051–65.
Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol. 2017;219:22–96.
Xu S, Ilyas I, Little PJ, Li H, Kamato D, Zheng X, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacol Rev. 2021;73:924–67.
Kawai Y, Nishikawa T, Shiba Y, Saito S, Murota K, Shibata N, et al. Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: implication in the anti-atherosclerotic mechanism of dietary flavonoids. J Biol Chem. 2008;283:9424–34.
Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko AV, Orekhov AN. Mechanisms of foam cell formation in atherosclerosis. J Mol Med. 2017;95:1153–65.
Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med. 2002;8:1235–42.
Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis. Nat Rev Cardiol. 2020;17:387–401.
Fan L, Liu JW, Hu W, Chen ZX, Lan J, Zhang TT, et al. Targeting pro-inflammatory T cells as a novel therapeutic approach to potentially resolve atherosclerosis in humans. Cell Res. 2024;34:407–27.
Grootaert MOJ, Bennett MR. Vascular smooth muscle cells in atherosclerosis: time for a re-assessment. Cardiovasc Res. 2021;117:2326–39.
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–72.
Acknowledgements
This work was funded by grants from the National Natural Science Foundation of China (82192912), National Engineering Research Center of TCM Standardization Technology (2023-ZYBZH-10), and National Key R&D Program “Strategic Scientific and Technological Innovation Cooperation” Key Project (2022YFE0203600).
Author information
Authors and Affiliations
Contributions
CL, CC, GWF, CRM, and XMG participated in the research design; CC, RRH, CRM, XH, YXD, HL, ZXC, XHY, TW, WXY, JQW, FQW, FFD, and YR conducted the experiments; CC, CL, CRM, RRH, and HL performed the data analysis; CL, CC, CRM, and GWF wrote or contributed to the writing of the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
He, Rr., Ma, Cr., He, X. et al. Circulating metabolites of Borneolum syntheticum (Bingpian) ameliorate atherosclerosis in ApoE−/− mice via inhibiting macrophage foam-cell formation. Acta Pharmacol Sin 46, 759–776 (2025). https://doi.org/10.1038/s41401-024-01406-5
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41401-024-01406-5
Keywords
This article is cited by
-
Compound Danshen decoction identifies its mechanism of antagonizing atherosclerosis by network pharmacology and transcriptomics
Naunyn-Schmiedeberg's Archives of Pharmacology (2025)
